Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 318

1.

Reduction of invasive pneumococcal disease 3 years after the introduction of the 13-valent conjugate vaccine in the Oxfordshire region of England.

Moore CE, Paul J, Foster D, Mahar SA, Griffiths D, Knox K, Peto TE, Walker AS, Crook DW; Oxford Invasive Pneumococcal Surveillance Group.

J Infect Dis. 2014 Oct 1;210(7):1001-11. doi: 10.1093/infdis/jiu213. Epub 2014 Apr 9.

2.

Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.

Steens A, Bergsaker MA, Aaberge IS, Rønning K, Vestrheim DF.

Vaccine. 2013 Dec 16;31(52):6232-8. doi: 10.1016/j.vaccine.2013.10.032. Epub 2013 Oct 29.

PMID:
24176490
3.

Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.

Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MP, Miller E.

Lancet Infect Dis. 2015 May;15(5):535-43. doi: 10.1016/S1473-3099(15)70044-7. Epub 2015 Mar 20. Erratum in: Lancet Infect Dis. 2015 Jun;15(6):629.

4.

Nearly complete elimination of the 7-valent pneumococcal conjugate vaccine serotypes in Tennessee.

Halasa NB, Grijalva CG, Arbogast PG, Talbot TR, Craig AS, Griffin MR, Schaffner W.

Pediatr Infect Dis J. 2013 Jun;32(6):604-9. doi: 10.1097/INF.0b013e318287fe0d.

PMID:
23348816
5.

Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance.

Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, Petit S, Zansky SM, Harrison LH, Reingold A, Miller L, Scherzinger K, Thomas A, Farley MM, Zell ER, Taylor TH Jr, Pondo T, Rodgers L, McGee L, Beall B, Jorgensen JH, Whitney CG.

Lancet Infect Dis. 2015 Mar;15(3):301-9. doi: 10.1016/S1473-3099(14)71081-3. Epub 2015 Feb 3.

6.

Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.

Lepoutre A, Varon E, Georges S, Dorléans F, Janoir C, Gutmann L, Lévy-Bruhl D; Microbiologists of Epibac; ORP Networks.

Vaccine. 2015 Jan 3;33(2):359-66. doi: 10.1016/j.vaccine.2014.11.011. Epub 2014 Nov 20.

PMID:
25448105
7.

Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010-2020.

Link-Gelles R, Taylor T, Moore MR; Active Bacterial Core Surveillance Team.

Vaccine. 2013 May 24;31(22):2572-7. doi: 10.1016/j.vaccine.2013.03.049. Epub 2013 Apr 11.

PMID:
23583813
8.

Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012.

Demczuk WH, Martin I, Griffith A, Lefebvre B, McGeer A, Lovgren M, Tyrrell GJ, Desai S, Sherrard L, Adam H, Gilmour M, Zhanel GG; Toronto Bacterial Diseases Network; Canadian Public Health Laboratory Network.

Can J Microbiol. 2013 Dec;59(12):778-88. doi: 10.1139/cjm-2013-0614. Epub 2013 Oct 21.

PMID:
24313450
9.

Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance.

Ben-Shimol S, Greenberg D, Givon-Lavi N, Schlesinger Y, Somekh E, Aviner S, Miron D, Dagan R.

Vaccine. 2014 Jun 5;32(27):3452-9. doi: 10.1016/j.vaccine.2014.03.065. Epub 2014 Mar 30.

PMID:
24690148
11.

Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England.

van Hoek AJ, Sheppard CL, Andrews NJ, Waight PA, Slack MP, Harrison TG, Ladhani SN, Miller E.

Vaccine. 2014 Jul 23;32(34):4349-55. doi: 10.1016/j.vaccine.2014.03.017. Epub 2014 Mar 21.

PMID:
24657717
12.

Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality.

Harboe ZB, Dalby T, Weinberger DM, Benfield T, Mølbak K, Slotved HC, Suppli CH, Konradsen HB, Valentiner-Branth P.

Clin Infect Dis. 2014 Oct 15;59(8):1066-73. doi: 10.1093/cid/ciu524. Epub 2014 Jul 16. Erratum in: Clin Infect Dis. 2014 Dec 15;59(12):1812.

13.

Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.

Lacapa R, Bliss SJ, Larzelere-Hinton F, Eagle KJ, McGinty DJ, Parkinson AJ, Santosham M, Craig MJ, O'Brien KL.

Clin Infect Dis. 2008 Aug 15;47(4):476-84. doi: 10.1086/590001.

14.

Pediatric invasive pneumococcal disease caused by vaccine serotypes following the introduction of conjugate vaccination in Denmark.

Harboe ZB, Valentiner-Branth P, Ingels H, Rasmussen JN, Andersen PH, Bjerre CC, Goldblatt D, Ashton L, Haston M, Konradsen HB, Lambertsen L; Danish Pneumococcal Surveillance Collaborating Group.

PLoS One. 2013;8(1):e51460. doi: 10.1371/journal.pone.0051460. Epub 2013 Jan 24.

15.

Pneumococcal carriage and invasive disease in children before introduction of the 13-valent conjugate vaccine: comparison with the era before 7-valent conjugate vaccine.

Sharma D, Baughman W, Holst A, Thomas S, Jackson D, da Gloria Carvalho M, Beall B, Satola S, Jerris R, Jain S, Farley MM, Nuorti JP.

Pediatr Infect Dis J. 2013 Feb;32(2):e45-53. doi: 10.1097/INF.0b013e3182788fdd.

PMID:
23080290
16.

Invasive Pneumococcal Disease Following the Introduction of 13-Valent Conjugate Vaccine in Children in New York City From 2007 to 2012.

Farnham AC, Zimmerman CM, Papadouka V, Konty KJ, Zucker JR, Nattanmai GV, Jose S, Rosen JB.

JAMA Pediatr. 2015 Jul;169(7):646-52. doi: 10.1001/jamapediatrics.2015.0612.

PMID:
25938798
17.

Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.

Klok RM, Lindkvist RM, Ekelund M, Farkouh RA, Strutton DR.

Clin Ther. 2013 Feb;35(2):119-34. doi: 10.1016/j.clinthera.2012.12.006. Epub 2013 Jan 10.

PMID:
23312274
18.

Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2010 Mar 12;59(9):253-7.

19.

Have changing pneumococcal vaccination programmes impacted disease in Ontario?

Lim GH, Wormsbecker AE, McGeer A, Pillai DR, Gubbay JB, Rudnick W, Low DE, Green K, Crowcroft NS, Deeks SL.

Vaccine. 2013 May 31;31(24):2680-5. doi: 10.1016/j.vaccine.2013.04.007. Epub 2013 Apr 16.

PMID:
23597716
20.

Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995-2011.

Rudnick W, Liu Z, Shigayeva A, Low DE, Green K, Plevneshi A, Devlin R, Downey J, Katz K, Kitai I, Krajden S, Ostrowska K, Richardson D, Richardson S, Sarabia A, Silverman M, Simor AE, Tyrrell G, McGeer A; Toronto Invasive Bacterial Diseases Network.

Vaccine. 2013 Dec 2;31(49):5863-71. doi: 10.1016/j.vaccine.2013.09.049. Epub 2013 Oct 5.

PMID:
24099873
Items per page

Supplemental Content

Write to the Help Desk